|Table of Contents|

Research progress on anti-tumor effect of TNBG and its derivatives

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 13
Page:
2557-2562
Research Field:
Publishing date:

Info

Title:
Research progress on anti-tumor effect of TNBG and its derivatives
Author(s):
CHEN Jiezhong1; ZHENG Xiaohong2; YU Yu3
1.Department of Medical Nursing,Jiyuan Vocational and Technical College,Henan Jiyuan 459000,China;2.School of Pharmacy,Chongqing Medical and Pharmaceutical College,Chongqing 401331,China;3.College of Pharmaceutical Science,Chongqing Medicinal University,Chongqing 400016,China.
Keywords:
TNBG; tumor; drug; lipid metabolism
PACS:
R730.5
DOI:
10.3969/j.issn.1672-4992.2023.13.036
Abstract:
Lipid metabolism plays an important role in tumor development and invasion,and has become one of the most important metabolic markers of tumor cells.PPARγ ligands or agonists have good anti-tumor effects on a variety of tumors.TNBG is an innovative anti-tumor drug developed independently.In vitro and in vivo experiments show that it has significant anti-tumor effect,presenting non cytotoxicit.It has been confirmed that PPARγ is its target.In this paper,the anti-tumor effects and mechanisms of TNBG and its derivatives are reviewed.

References:

［1］BROADFIELD LA,PANE AA,TALEBI A,et al.Lipid metabolism in cancer:New perspectives and emerging mechanisms［J］.Dev Cell，2021,56(10):1363-1393.
［2］SUN Z,JIANG Q,LI J,et al.The potent roles of Salt-Inducible Kinases (SIKs) in metabolic homeostasis and tumorigenesis［J］.Signal Transduct Target Ther，2020,5(1):150.
［3］LLU RZ,GODBOUT R.An amplified fatty acid-binding protein gene cluster in prostate cancer:emerging roles in lipid metabolism and metastasis［J］.Cancers，2020,12(12):3823.
［4］HUANG S,GUO Y,LI Z,et al.Systematic review of metabolomic profiling of gastric cancer and esophageal cancer［J］.Cancer Biol Med，2020,17(1):181-198.
［5］CHENG S,WANG G,WANG Y,et al.Fatty acid oxidation inhibitor etomoxir suppresses tumor progression and induces cell cycle arrest via PPARγ-mediated pathway in bladder cancer［J］.Clin Sci，2019,133(15):1745-1758.
［6］RHRIG F,SCHULZE A.The multifaceted roles of fatty acid synthesis in cancers［J］.Nat Rev Cancer，2016,16(11):732-749.
［7］SNAEBJORNSSON MT,JANAKI-RAMAN S,SCHULZE A.Greasing the wheels of the cancer machine:the role of lipid metabolism in cancers［J］.Cell Metab，2020,31(1):62-76.
［8］余瑜.一种氮杂甾体化合物制备及其用途［P］.中国,CN1124251A,1996-06-12. YU Y.A kind of aza-steroid compound preparation and use［P］.China,CN1124251A,1996-06-12.
［9］余瑜,李龙江,汤为学,等.创新构型非细胞毒性抗肿瘤新药TNBG新作用机制的研究［C］.上海:中国科协第五届青年学术年会论文集，2004:253-254. YU Y,LI LJ,TANG WX,et al.Study on the new mechanism of non cytotoxic anti-tumor drug TNBG with innovative configuration［C］.Shanghai:Proceedings of the Fifth Youth Academic Annual Conference of China Association for Science and Technology，2004:253-254.
［10］刘嫱,陈志琼,杨菲,等.反相高效液相色谱法测定小鼠血浆中德氮吡格［J］.西南大学学报(自然科学版),2008,30(07):117-120. LIU Q,CHEN ZQ,YANG F,et al.Determination of TNBG in plasma by RP-HPLC［J］.Journal of Southwest University （Natural Science Edition）,2008,30(07):117-120.
［11］YUAN Y,LI W,LI L,et al.Effects of tetrazanbigen on the protein expression in human hepatocellular carcinoma cell line QGY-7701［J］.J Huazhong Univ Sci Technolog Med Sci，2009,29(3):304-308.
［12］陈洁忠,郑小红,段雯,等.1-氯甲基-1,2,3,4-四氢异喹啉盐酸盐的制备［J］.中国医药工业杂志,2009,40(03):178-179. CHEN JZ,ZHENG XH,DUAN W,et al.Preparation of 1-chloromethyl-1,2,3,4-tetrahydroisoquinoline hydrochloride［J］.Chinese Journal of Pharmaceuticals,2009,40(03):178-179.
［13］程训官,郑小红,夏铸,等.1-氨甲基-1,2,3,4-四氢异喹啉的合成研究［C］.重庆:中国化学会全国第三届有机合成化学与过程学术讨论会论文摘要集，2010:174-175. CHENG XG,ZHENG XH,XIA Z,et al.Synthesis of 1-aminomethyl-1,2,3,4-tetrahydroisoquinoline hydrochloride［C］.Chongqing:Abstracts of the Third National Symposium on Organic Synthetic Chemistry and Processes,Chinese Chemical Society，2010:174-175.
［14］罗宗伟.喹喔啉及其衍生物的合成研究［D］.重庆:重庆医科大学,2007. LUO ZW.Synthesis of quinoxaline and its derivatives［D］.Chongqing:Chongqing Medical University,2007.
［15］甘淋玲.新型抗肿瘤TNBG衍生物的设计合成及构效关系研究［D］.重庆:重庆医科大学,2020. GAN LL.Design,synthesis and structure-activity relationship of novel TNBG derivatives as antitumor agent［D］.Chongqing:Chongqing Medical University,2020.
［16］LI LJ,YU Y,TANG WX,et al.Effects of TNBG on the proliferation and apoptosis of human hepatocellular carcinoma cell line QGY-7701［J］.Journal of Sichuan University(Medical Science Edition)，2005,36(3):372-374.
［17］YOON H,SHAW JL,HAIGIS MC,et al.Lipid metabolism in sickness and in health:Emerging regulators of lipotoxicity［J］.Mol Cell,2021,81(18):3708-3730.
［18］李龙江.创新构型抗肿瘤新药德氮吡格的作用机制探讨［D］.重庆:重庆医科大学,2005. LI LJ.A survey on the mechanism of a new antitumor drug TNBG with novel configuratton［D］.Chongqing:Chongqing Medical University,2005.
［19］ELIX C,PAL SK,JONES JO.The role of peroxisome proliferator-activated receptor gamma in prostate cancer［J］.Asian J Androl，2018,20(3):238-243.
［20］WILSON HE,STANTON DA,RELLICK S,et al.Breast cancer-associated skeletal muscle mitochondrial dysfunction and lipid accumulation is reversed by PPARG［J］.Am J Physiol Cell Physiol，2021,320(4):C577-C590.
［21］BUROTTO M,SZABO E.PPARγ in head and neck cancer prevention［J］.Oral Oncol，2014,50(10):924-929.
［22］MATSUDA M,KORN BS,HAMMER RE,et al.SREBP cleavage-activating protein (SCAP) is required for increased lipid synthesis in liver induced by cholesterol deprivation and insulin elevation［J］.Genes Dev，2001,15(10):1206-1216.
［23］袁拥华,杨晓兰,李伟,等.德氮吡格对人肝癌细胞QGY-7701的亚细胞蛋白质组学研究［C］.重庆:2009年脂质代谢与器官损害国际学术研讨会论文摘要集，2009:149-150. YUAN YH,YANG XL,LI W,et al.Subcellular proteomic analysis of Tetrazanbigen on human hepatocellular carcinoma cell line QGY-7701［C］.Chongqing:Abstracts of International Symposium on Lipid Metabolism and Organ Damage in 2009，2009:149-150.
［24］李龙江,杨晓兰,袁拥华,等.德氮吡格对人肝癌细胞株QGY-7701基因表达的影响［J］.第三军医大学学报,2006,28(02):151-153. LI LJ,YANG XL,YUAN YH,et al.Changes of gene expression of human hepatocellular carcinoma cell line QGY-7701 induced by tetrazanbigen［J］.Acta Academiae Medicinae Militaris Tertiae,2006,28(02):151-153.
［25］FAN X,XU D,LU B,et al.Improving the refolding of NTA protein by urea gradient and arginine gradient size-exclusion chromatography［J］.J Biochem Biophys Methods，2008,70(6):1130-1138.
［26］FONSECA RG,FERREIRA TL,WARD RJ.Refolding and purification of the human secreted group IID phospholipase A2 expressed as inclusion bodies in Escherichia coli［J］.Protein Expr Purif，2009,67(2):82-87.
［27］李伟,张雪梅,郑晓红,等.尺寸排阻色谱柱上尿素梯度复性全长人PPAR-γ［J］.光谱实验室,2010,27(04):1614-1620. LI W,ZHANG XM,ZHENG XH,et al.On-column refolding of full-length human PPAR-γ by urea gradient size-exclusion chromatography［J］.Chinese Journal of Spectroscopy Laboratory,2010,27(04):1614-1620.
［28］李伟.创新抗癌药徳氮吡格作用PPARγ靶点的研究［D］.重庆:重庆医科大学,2009. LI W.Study on PPARγ target for novel antitumour drug tetraznbigen［D］.Chongqing:Chongqing Medical University,2009.
［29］LOS M,BUREK CJ,STROH C,et al.Anticancer drugs of tomorrow:apoptotic pathways as targets for drug design［J］.Drug Discov Today，2003,8(2):67-77.
［30］SGAL-BENDIRDJIAN E,HILLION J,BELMOKHTAR CA.Current concepts on apoptotic signalling pathways:new targets for anticancer strategies［J］.Bull Cancer，2003,90(1):9-17.
［31］UNGER RH.The physiology of cellular liporegulation［J］.Annu Rev Physiol，2003,65:333-347.
［32］STRAUSS B,HARRISON A,COELHO PA,et al.Cyclin B1 is essential for mitosis in mouse embryos,and its nuclear export sets the time for mitosis［J］.J Cell Biol，2018,217(1):179-193.
［33］YE C,WANG J,WU P,et al.Prognostic role of cyclin B1 in solid tumors:a meta-analysis［J］.Oncotarget，2017,8(2):2224-2232.
［34］李龙江,陈志琼,汤为学,等.德氮吡格对人肝癌细胞株增殖抑制的体外研究［J］.重庆医科大学学报,2005,30(03):345-347. LI LJ,CHEN ZQ,TANG WX,et al.Inhibition of proliferation of human hepatocellular carcinoma cell lines by TNBG in vitro［J］.Journal of Chongqing Medical University,2005,30(03):345-347.
［35］郑小红,李伟,张昕宇,等.新型手性抗肿瘤药物德氮吡格(TNBG)体外抗肿瘤活性初步研究［J］.世界科技研究与发展,2011,33(3):477-480. ZHENG XH,LI W,ZHANG XY,et al.Researches on antitumor activity of novel chiral compound TNBG in vitro［J］.World Sci-Tech R & D,2011,33(3):477-480.
［36］郑小红.创新脂毒性抗癌药物德氮吡格药效学及作用机制研究［D］.重庆:重庆医科大学,2011. ZHENG XH.Study on the antitumor effects and the lipotoxicity mechanism of TNBG with novel configuration［D］.Chongqing:Chongqing Medical University,2011.
［37］ZHENG X,LI W,LAN Z,et al.Antitumour effects of tetrazanbigen against human hepatocellular carcinoma QGY-7701 through inducing lipid accumulation in vitro and in vivo［J］.J Pharm Pharmacol，2015,67(11):1593-1602.
［38］刘嫱,陈志琼,梁艳,等.固相萃取-高效液相色谱法测定小鼠血浆中德氮吡格［J］.药物分析杂志,2009,29(04):617-619. LIU Q,CHEN ZQ,LIANG Y,et al.SPE－HPLC determination of tetrazanbigen in mice plasma［J］.Chinese Journal of Pharmaceutical Analysis,2009,29(04):617-619.
［39］刘嫱,邝少轶,陈志琼,等.静脉注射德氮吡格在小鼠的组织分布及排泄研究［J］.中国药理学通报,2013,29(1):142-143. LIU Q,KUANG SY,CHEN ZQ,et al.Biodistribution and excretion of Tetrazanbigen in mice［J］.Chinese Pharmacological Bulletin,2013,29(1):142-143.
［40］朱必敏.抗癌新药德氮吡格及其衍生物的构效关系与作用模式［D］.重庆:重庆医科大学,2013. ZHU BM.The structure-antivity relationship and interaction of the new antitumor TNBG and its derivatives［D］.Chongqing:Chongqing Medical University,2013.
［41］李耀伟.抗肝癌新药德氮吡格衍生物的设计与合成研究［D］.重庆:重庆医科大学,2019. LI YW.Design and synthesis of derivatives of anti-hepatocarcinoma drug Tetrazanbigen［D］.Chongqing:Chongqing Medical University,2019.
［42］CHEN X,GAN YJ,YU Y,et al.Synthesis and evaluation of new sterol derivatives as potential antitumor agents［J］.RSC Adv，2018,8(47):26528-26537.
［43］GAN L,GAN Z,DAN Y,et al.Tetrazanbigen derivatives as peroxisome proliferator-activated receptor gamma (PPARγ) partial agonists:design,synthesis,structure-activity relationship,and anticancer activities［J］.J Med Chem，2021,64(2):1018-1036.
［44］GONZLEZ-MAGAA A,BLANCO FJ.Human PCNA structure,function and interactions［J］.Biomolecules，2020,10(4):570.
［45］HU X,WAN C,GAN Z,et al.TNBG-5602,a novel derivative of quinoxaline,inhibits liver cancer growth via upregulating peroxisome proliferator-activated receptor γ in vitro and in vivo［J］.J Pharm Pharmacol，2019,71(11):1684-1694.
［46］胡雪莲.应用人全基因组siRNA文库筛选并阐述创新型新药TNBG-5602抗肝癌作用的机制［D］.重庆:重庆医科大学,2018. HU XL.Study on the antitumor mechanism of TNBG-5602 using a human genomic siRNA library ［D］.Chongqing:Chongqing Medical University,2018.
［47］SELVAM C,MUTISYA D,PRAKASH S,et al.Therapeutic potential of chemically modified siRNA:Recent trends［J］.Chem Biol Drug Des，2017,90(5):665-678.
［48］ELBASHIR S,HARBORTH J,LENDECKEL W,et al.Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells ［J］.Nature，2001,411(6836):494-498.
［49］HANNON GJ,ROSSI JJ.Unlocking the potential of the human genome with RNA interference［J］.Nature，2004,431(7006):371-378.
［50］LI J,YEN C,LIAW D,et al.PTEN,a putative protein tyrosine phosphatase gene mutated in human brain,breast,and prostate cancer［J］.Science，1997,275:1943-1947.
［51］HE Y,SUN MM,ZHANG GG,et al.Targeting PI3K/Akt signal transduction for cancer therapy［J］.Signal Transduct Target Ther，2021,6(1):425.
［52］WANG J,LI Y,WAN CM,et al.PTEN inhibition leads to the development of resistance to novel isoquinoline derivative TNBG-5602 in human liver cancer cells［J］.Am J Cancer Res，2021,11(9):4515-4527.
［53］LI R,ZHOU S,GAN Z,et al.The biological fate of a novel anticancer drug candidate TNBG-5602:Metabolic profile,interaction with CYP450,and pharmacokinetics in rats［J］.Molecules，2022,27(8):2594.
［54］但彦肜.新型抗肿瘤德氮吡格衍生物T-1019的药效学及作用机制研究［D］.重庆:重庆医科大学,2021. DAN YR.Pharmacodynamices and mechanism of novel antitumor tetrazanbigen derivative T-1019［D］.Chongqing:Chongqing Medical University,2021.

Memo

Memo:
National Natural Science Foundation of China(No.30171070,30371632,30772595）；国家自然科学基金项目(编号：30171070,30371632,30772595)
Last Update: 2023-05-31